Evidence map›Paper›PMID 41190966›Full record

ArticleCytotherapy2026

Pilot study of early BK polyomavirus in the urine and risk of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.

Yeon Joo Lee, Yuxuan Li, Michael Scordo, Gyuri Han, Ilya Glezerman, Brian Shaffer, Sergio A Giralt, Esperanza B Papadopoulos, Miguel-Angel Perales, Ann A Jakubowski and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yeon Joo LeeInfectious Diseases and Allergy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA. Electronic address: leey3@mskcc.org.
Yuxuan LiInfectious Diseases and Allergy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Michael ScordoAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Gyuri HanInfectious Diseases and Allergy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ilya GlezermanRenal Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Brian ShafferAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Sergio A GiraltAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Esperanza B PapadopoulosAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Miguel-Angel PeralesAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Ann A JakubowskiAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.
Genovefa A PapanicolaouInfectious Diseases and Allergy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Weill Cornell Medical College, Cornell University, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundBK polyomavirus (BKPyV)-associated hemorrhagic cystitis occurs in 7-60% of allogeneic hematopoietic cell transplantation (HCT) recipients and may cause significant morbidity.

objectiveWe conducted a pilot study to assess if early BKPyV viruria (≤day [D]+40 post-HCT) predicted risk for BKPyV hemorrhagic cystitis in the first year post-HCT. STUDY

designAdult consecutive allogeneic HCT recipients at Memorial Sloan Kettering Cancer Center from August 2019 through April 2021 were screened for urine BKPyV quantitative PCR (Eurofins Viracor, Lenexa, KS) between D-14 and D0 (pre-HCT). If the pretransplant test was negative, urine BKPyV was retested between D+20 and D+40 postengraftment. If the pre-HCT test was positive, repeat postengraftment testing was not performed. Patients with early BKPyV viruria were monitored by plasma BKPyV quantitative PCR bimonthly for the first 6 months post-HCT or 12 months post-HCT in patients with graft-versus-host disease requiring systemic corticosteroids. Patients were followed clinically for the development of BKPyV hemorrhagic cystitis in the first year post-HCT. Urine BKPyV PCR was checked per standard of care if patients developed symptoms of cystitis. BKPyV hemorrhagic cystitis was defined as BKPyV viruria with macroscopic hematuria and symptoms of cystitis. Risk factors for BKPyV hemorrhagic cystitis were examined using logistic regression models.

resultsOf 152 patients analyzed, 73 (48%) had early BKPyV viruria (33 pre-HCT and 40 post-HCT). Nine patients developed BKPyV hemorrhagic cystitis before D+40, and 7 patients after D+40. Among the 79 patients without early BKPyV viruria, none developed BKPyV hemorrhagic cystitis. The cumulative incidence of BKPyV hemorrhagic cystitis by 1-year post-HCT was 10% (95% confidence interval: 0.051-0.146). Cut point analysis demonstrated that BKPyV urine viral load ≥6.35 × 10

conclusionsNearly half of HCT patients had BKPyV viruria by D+40 post-HCT. Early BKPyV viruria ≥6.35 × 10

Indexed as

BK VirusCystitisHematopoietic Stem Cell TransplantationHemorrhagePolyomavirus InfectionsAdultAgedCystitis, HemorrhagicFemaleGraft vs Host DiseaseHumansMaleMiddle AgedPilot ProjectsRisk FactorsTransplantation, HomologousBK polyomavirushematopoietic cell transplantationhemorrhagic cystitis

Identifiers

PMID41190966
PMCPMC12616477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.